Continuous levodopa for advanced Parkinson's disease

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 3, 2007, Pages 335-348

  Lundqvist, Christofer ^a,b  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

Carbidopa; Levodopa; Levodopa carbidopa gel; Parkinson's disease

Indexed keywords

APOMORPHINE; BROMOCRIPTINE; CABERGOLINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CARBOXYMETHYLCELLULOSE; DOPAMINE RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; DUODOPA; ENTACAPONE; LEVODOPA; LISURIDE; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; FUNCTIONAL STATUS; HALF LIFE TIME; HALLUCINATION; HUMAN; INJECTION SITE FIBROSIS; INJECTION SITE INFLAMMATION; INTERMETHOD COMPARISON; LUNG FIBROSIS; MONOTHERAPY; MOTOR DYSFUNCTION; NAUSEA; NEUROSURGERY; PARKINSON DISEASE; QUALITY OF LIFE; SAFETY; SIDE EFFECT; SKIN PIGMENTATION; THROMBOPHLEBITIS;

EID: 34547700932     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Aarsland D, Larsen J P, Tandberg E, et al. 2000. Predictors of nursing home placement in Parkinsons disease: a population-based prospective study. J Am Geriatr Soc, 48:938-42.
2. Benabid AL. 2003. Deep brain stimulation for Parkinson's Disease. Curr Opin Neurobiol, 13:696-706.
3. Bredberg E, Nilsson D, Johansson K, et al. 1993. Intraduodenal infusion of a water-based levodopa dispersion for optimisation ofthe therapeutic effect in severe Parkinson's disease. Eur J Clin Pharmacol, 45:117-22.
4. Burkhard PR, Vingerhoets FJG, Berney A, et al. 2004. Suicide after successful deep brain stimulation for movement disorders. Neurology, 63:2170-2.
5. Cedarbaum JM, Silvestr M, Kutt H 1990. Sustained enteral aministration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology, 40:995-7.
6. Chaudhuri KR, Healy DG, Schapira AHV. 2006a. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol, 5:235-45,
7. Chaudhuri KR, Martinez-Martin P, Schapira AHV, et al. 2006b. International multicenter pilot study of the first comprehensive selfcompleted nonmotor symptoms questionnaire for Parkinsons disease: the NMSQuest Study. Move disord (E-pub ahead of print).
8. Colzi A, Turner K, Lees AJ. 1998. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry, 64:573-6.
9. de Gaspari D, Siri C, Landi A, et al. 2006. Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinsosn's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalanuc nucleus. J Neurol Neurosurg Psychiatry, 77:450-3.
10. Deuschl G, Schade-Brittinger C, Krack P, et al 2006. A randomized trial of deep-brain stimulation for Parkinsons disease. N Engl J Med, 355:896-908.
11. Deuschl G, Wenzelburger R, Kopper F, et al. 2003. Deep brain stimulation of the subthalamic nucleus for Parkinson's disease: a therapy approaching evidence-based standards. J Neurol, 250(Suppl 1):143-6.
12. Dewey RB, Hutton T, LeWitt PA, et al. 2001. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for Parkinsonian off-state events. Arch Neurol, 58:1385-92.
13. Dhawan V, Medcalf P, Stegie F, et al. 2005. Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinsons disease patents treated with cabergoline. J Neural Transm, 112:661-8.
14. Di Rosa AE, Epifanio A, Antonini A, et al. 2003. Continuous apomorphine infusion and neuropsychiatric disorders: a controlled study in patients with advanced Parkinson's disease. Neurol Sci, 24:174-5.
15. Diamond A, Jankovic J. 2005. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry, 76:1188-93.
16. Dodel R, Eggert KM, Singer MS, et al. 1998. Costs of drug treatment in Parkinsons disease. Mov disord, 13:249-54.
17. Dodel RC, Berger K, Oertel WH. 2001. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics, 19: 1013-38.
18. Esselink RAJ, deBie EMA, de Haan RJ, et al. 2004. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in PD. Neurology, 62:2017.
19. Fraix V, Houeto J-L, Lagrange E, et al. 2006. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry, 77:443-9.
20. Frankel JP, Kempster PA, Bovingdon M, et al. 1989. The effects of oral protein on the absorption of intraduodenal levodopa and motor performance. J Neurol Neurosurg Psychiatry, 52:1063-7.
21. Frankel JP, Lees AJ, Kempster PA, Stem GM. 1990. Subcutaneous apomorphine in the treatment of Parkinson's disease. J Neurol Neutosurg Psychiatry, 53:96-101.
22. Global Parkinson's disease survey steering committee. 2002. Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov disord, 17:60-7.
23. Goetz CG, Poewe W, Rascol O, et al. 2006. Eidence based medical review update: pharmacological and surgical treatments of Parkinsons disease: 2001 to 2004. Mov disord, 20:523-39.
24. Hardie RJ, Lees AJ, Stern GM. 1984. On-off fluctuations in Parkinson's disease. a clinical and neuropharmacological study. Brain, 107: pp 487-506.
25. Hardie RJ, Malcolm SL, Lees AJ, et al. 1996. The pharmacokinetics of intravenous and oral evodopa in patients with Parkinson's disease who exhibit on-off fluctuations. Br J Clin Pharmacol, 22:429-36.
26. Herzog J, Volkmann J, Krack P, et al. 2003. Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord, 18:1332-7.
27. Horvath J, Fross RD, Kleiner-Fisman G, et al. 2004. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov disord, 19:65 6-62.
28. Hughes AJ, Daniel SE, Kilford L, et al. 1992. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological Study of 100 cases, J Neurol Neurosurg Psychiatry, 55:181-4.
29. Kanovsky P, Kubova D, Bares M, et al. 2002. Levodopa-induced dysidnesias and continuous subcutaneous infusions of apomorphine: results of a two-year, prospective follow-up. Mov Disord, 17:188-91.
30. Krause W, Niewueboer B, Ruggieri S, et al. 1988. Pharmacokinetics of lisuride after subcutaneous infusion. J Neural Transm, (Suppl 27):71-4.
31. Kristiansen IS, Bingefors C, Nyholm D, et al. 2005. The cost-effectiveness of continuous duodenal delivery of levodopa (Duodopa) in patients with severe Parkinsons disease [abstract]. Mov disord, 20(Suppl 10):S80.
32. Kurlan R, Nutt JG, Woodward WR, et al. 1988. Duodenal and gastric delivery of levodopa in Parkinsonism. Ann Neurol, 23: 589-95.
33. Kurlan R, Rubin AJ, Miller C, et al. 1986. Duodenal delivery of levodopa for on-off fluctuations in Arkinsonism: preliminary observations. Ann Neurol, 20:262-5.
34. Kurth MC, Tetrud JW, Tanner CK et al. 1993. Double-blind, placebo-controlled, cross-over study of duodenal infirsion of levodopa/ carbidopa in Parkinson's disease patients with "on-off" fluctuations. Neurology, 43:1698-703.
35. Lagrange E, Krack P, Moro E, et al. 2002. Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology, 59:1976-8.
36. Lindgren P, von Campenhausen S, Spottke E, et al. 2005. Cost of Parkinsons disease in Europe. Eur J Neurol, 12: 68-73.
37. Meissner W, Trottenberg T, Klaffke S, et al. 2001. Apomorphinterapi versus tiefe hirnstimulation. Nervenarzt, 72:924-7.
38. Nicole E, Pollak P, Serre-Debeauvais F, et al. 1993. Pharmacokinetics of apomorphine in Parkinsonian patients. Fundam Clin Pharmacol, 7:245-52.
39. Nilsson D, Hansson LE, Johansson K, et al. 1998. Long-term intraduodenal infusion of a water based levodopa-carbidopa dispersion in very advanced Parkinson's disease. Acta Neurol Scand, 97:175-83.
40. Nilsson D, Nyholm D, Aquilonius SM. 2001. Duodenal levodopa infusion in Parkinson's disease - long-term experience. Acta Neurol Scand, 104:343-8.
41. Nugroho AK, Li L, Dijkstra D, et al. 2005. Transdermal iontophoresis of the dopamine agonist 5-OH-DPAT in human skin in vitro. J Contr Rel, 103:393-403.
42. Nutt JG, Carter JH, Lea ES, et al. 1997. Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Mov Disord, 12:285-92.
43. Nutt JG, Woodward WR, Anderson JL. 1984. The "on-off" phenomenon in Parkinsons disease. Relation to levodopa absorption and transport. N Engl J Med, 310:483-8.
44. Nutt JG, Woodward WR, Anderson JL. 1985. The effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: the mechanism of action in the treatment of Parkinsonism. Ann Neurol, 18:537-43.
45. Nyholm D, Askmark H, Gomes-Trolin C, et al. 2003. Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. Clin Neuropharmacol, 26:156-63.
46. Nyholm D, Jansson R, Willows T, et al. 2005a. Long-term 24 hour duodenal infusion of levodopa: outcome and dose requirements. Neurology, 65:1506-7.
47. Nyholm D, Lewander T, Johansson A, et al. 2007. Enteral levodopoda/ carbidopa infusion in advanced Parkinson's disease: long term exposure. Clin Neuropharmacol. In press.
48. Nyholm D, Nilsson Remahl I, et al. 2005b. Duodenal levodopa infusion monotherapy vs oral polypharmay in advanced Parkinson disease. Neurology, 64:216-23.
49. Olanow CW, Agid Y, Mizuno Y, et al. 2004. Levodopa in the treatment of Parkinson's disease: current controversies. Mov disord, 19:997-1005.
50. Olanow CW, Watts RL, Koller WC. 2001. An algorithm (decision tree) for the management of Parkinsons disease (201): Treatment Guidelines. Neurology, 56:-88.
51. Pahwa R, Factor SA, Lyons KE, et al. 2006. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based Review): Report of the Quality Standards Subcommittee of the American Academy of Neruology. Neurology, 66:983-95.
52. Pfeiffer RE. 2005 A. Promising new technology for Parkinsons disease. Neurology, 65:S6-10.
53. Poewe W, Luessi F. 2005. Clinical studies with transdermal rotigotine in early Parkinsons disease. Neurology, 65:S11-14.
54. Priano L, Albani G, Brioschi A, et al. 2004. Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease. Mov disord, 19:937-42.
55. Quinn N, Parkes JD, Marsden CD. 1984. Control of on/off phenomenon by continuous intravenous inftision of levodopa. Neurology, 34:1131-6.
56. Rodríguez-Oroz MC, Obeso JA, Lang AE, et al. 2005. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain, 128:2240-9.
57. Ruggieri S, Stocchi F, Carta A, et al. 1989. Jejunal delivery of levodopa methyl ester. Lancet, 2:45-6.
58. Ruggieri S, Stocchi F, Carta A, et al. 1988. Comparison between levodopa and lisuride intravenous infusions: A clinical study. Mov disord, 3:313-19.
59. Russmann H, Ghika J, Villemure J-G, et al. 2004. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology, 63:1952-4.
60. Sage JI, Mark MH. 1991. Nighttime levodopa infusions to treat motor Fluctuations in advanced Parkinsosn disease: preliminary observations. Ann Neurol, 30:616-17.
61. Sage JI, McHale DM, Sonsalla P, et al. 1989a. Continuous levodopa infusions to treat complex dystonia in Parkinson's disease. Neurology, 39:888-91.
62. Sage JI, Schuh L, Heikkila RE, et al. 1988a. Continuous duodenal infusions of levodopa: plasma concentrations and motor fluctuations in Parkinson's disease. Clin Neuropharmacol, 11:36-44.
63. Sage JI, Trooskin S, Sonsalla P, et al. 1989b. Experience with continuous enteral levodopa infusions in the treatment of 9 patients with advanced Parkinsons disease. Neurology, 39:60-3.
64. Sage JI, Trooskin S, Sonsalla PK, et al. 1988b. Long-term duodenal infusion of levodopa for motor fluctuations in Parkinsonism. Ann Neurol, 24:87-9.
65. Schrag A, Jahanshahi M, Quinn N. 2000. What contributes to quality of life in patients with Parkinsons disease. J Neurol Neurosurg Psychiatry, 69:308-12.
66. Schuh LA, Bennett JP Jr. 1993. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of Parkinsonism in patients with advanced Parkinson's disease. Neurology, 43:1545-50.
67. Schwab RS, Amador LV, Lettvin JY. 1951. Apomorphine in Parkinson's disease. Trans Am Neurol Assoc, 56:251-3.
68. Shoulson I, Glaubiger GA, Chase TN. 1975. On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in Parkinsonian patients. Neurology, 25:1144-8.
69. Steiger MJ, Quinn NP, Marsden CD. 1992. The clinical use of apomorphine in Parkinson's disease. J Neurol, 239:389-93.
70. Stocchi F. 2005. Optimising levodopa therapy for the management of Parkinsons disease. J Neurol, 252:IV/43-IV/48.
71. Stocchi F, Olanow CW 2004. Continuous dopaminergic stimulation in early and advanced Parkinson's disease. Neurology, 62:S56-S63.
72. Stocchi F, Ruggieri S, Carta A, et al. 1992. Intravenous boluses and continuous infusion of L-dopa methyl ester in fluctuating patients with Parkinson's disease. Mov disord, 7:249-56.
73. Stocchi F, Vacca L, De Pandis MF, et al. 2001. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci, 22:93-4.
74. Stocchi F, Vacca L, Ruggieri S, et al. 2005. Intermittent vs. continuous levodopa administration in patients with advanced Parkinson's disease. Arch Neurol, 62:905-10.
75. Syed N, Murphy J, Zimmerman T, et al. 1998. Ten years experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease. Mov disord, 13:336-8.
76. Tagliati M, Pourfar MH, Alterman RL. 2005. Comment on: subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology, 65:179-80.
77. The Parkinson study group. 2003. A controlled trial of rotigotine monotherapy in early Parkinsons disease. Arch Neurol, 60:1721-8.
78. Vaamonde J, Luquin MR, Obeso JR. 1991. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain, 114:601-17.
79. van Camp G, Flamez A, Cosyns B, et al. 2004. Treatment of Parkinsons disease with pergolide and relation to restrictive valvular heart disease. Lancet, 363:1179-83.
80. Verhagen Metman L, Gillespie M, Farmer C, et al. 2001. Continuous transdermal dopaminergic, stimulation in advanced Parkinsons disease. Clin Neuropharmacol, 24:163-9.
81. von Campenhausen S, Bornschein B, Wick R, et al. 2005. Prevalence and incidence of Parkinsons disease in Europe. Eur Neuropsychopharmacol, 15:473-90.
82. Westin J, Nyholm D, Groth T, et al. 2006. Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinsons disease. Parkinsonism Relat Disord (E-pub ahead of print).
83. Widner H. 2003. Strategies to modify levodopa treatment. Adv Neurol, 91:229-36.